{
    "id": 14631,
    "fullName": "CSF3R S783fs",
    "impact": "frameshift",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "CSF3R S783fs results in a change in the amino acid sequence of the Csf3r protein beginning at aa 783 of 836, likely resulting in premature truncation of the functional protein (UniProt.org). S783fs does not result in increased Stat3 activation (PMID: 23656643, PMID: 24403076), however, results in increased Src activation and transformation in cell culture (PMID: 23656643), and therefore, is predicted to result in a gain of Csf3r protein function.",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 17123,
                    "pubMedId": 24403076,
                    "title": "Ligand independence of the T618I mutation in the colony-stimulating factor 3 receptor (CSF3R) protein results from loss of O-linked glycosylation and increased receptor dimerization.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24403076"
                },
                {
                    "id": 3951,
                    "pubMedId": 23656643,
                    "title": "Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23656643"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1441,
        "geneSymbol": "CSF3R",
        "terms": [
            "CSF3R",
            "CD114",
            "GCSFR",
            "SCN7"
        ]
    },
    "variant": "S783fs",
    "createDate": "12/01/2015",
    "updateDate": "01/13/2020",
    "referenceTranscriptCoordinates": {
        "id": 121557,
        "transcript": "NM_000760",
        "gDna": "chr1:g.(36466521_36466522)",
        "cDna": "c.(2347_2346)",
        "protein": "p.S783fs",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19749,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells derived from a patient with chronic neutrophilic leukemia harboring CSF3R S783fs did not respond to treatment with Pyridone 6 (CMP6) in culture (PMID: 23656643).",
            "molecularProfile": {
                "id": 14888,
                "profileName": "CSF3R S783fs"
            },
            "therapy": {
                "id": 2797,
                "therapyName": "Pyridone 6",
                "synonyms": null
            },
            "indication": {
                "id": 80187,
                "name": "chronic neutrophilic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 3951,
                    "pubMedId": 23656643,
                    "title": "Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23656643"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19750,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells derived from a patient with chronic neutrophilic leukemia harboring CSF3R S783fs did not respond to treatment with Xeljanz (tofacitinib) in culture (PMID: 23656643).",
            "molecularProfile": {
                "id": 14888,
                "profileName": "CSF3R S783fs"
            },
            "therapy": {
                "id": 941,
                "therapyName": "Tofacitinib",
                "synonyms": null
            },
            "indication": {
                "id": 80187,
                "name": "chronic neutrophilic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 3951,
                    "pubMedId": 23656643,
                    "title": "Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23656643"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19731,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells derived from a patient with chronic neutrophilic leukemia harboring CSF3R S783fs demonstrated sensitive to treatment with Sprycel (dasatinib) in culture (PMID: 23656643).",
            "molecularProfile": {
                "id": 14888,
                "profileName": "CSF3R S783fs"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 80187,
                "name": "chronic neutrophilic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3951,
                    "pubMedId": 23656643,
                    "title": "Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23656643"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19751,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells derived from a patient with chronic neutrophilic leukemia harboring CSF3R S783fs did not respond to treatment with Momelotinib (CYT387) in culture (PMID: 23656643).",
            "molecularProfile": {
                "id": 14888,
                "profileName": "CSF3R S783fs"
            },
            "therapy": {
                "id": 823,
                "therapyName": "Momelotinib",
                "synonyms": null
            },
            "indication": {
                "id": 80187,
                "name": "chronic neutrophilic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 3951,
                    "pubMedId": 23656643,
                    "title": "Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23656643"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 14888,
            "profileName": "CSF3R S783fs",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 121557,
            "transcript": "NM_000760",
            "gDna": "chr1:g.(36466521_36466522)",
            "cDna": "c.(2347_2346)",
            "protein": "p.S783fs",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}